Evaluating the relationship between biomarkers of potential harm and biomarkers of tobacco exposure among current, past, and nonsmokers: data from the National Health and Nutrition Examination Survey 2007–2012

Biomarkers

Volumn 22, Issue 5, 2017, Pages 403-412

  Saxena, Kunal ^a   Liang, Qiwei ^b   Muhammad Kah, Raheema ^b   Sarkar, Mohamadi ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Altria Client Services   (United States)

Author keywords

Biomarkers of exposure; biomarkers of potential harm; cigarette; cigarette smoking; current smokers; National Health and Nutrition Examination Survey; never smokers; past smokers; serum cotinine; smoking status

Indexed keywords

1 HYDROXYPYRENE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; APOLIPOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CIGARETTE SMOKE; COTININE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG URINE LEVEL; ENVIRONMENTAL EXPOSURE; ETHNICITY; FEMALE; GROUPS BY AGE; HAZARD ASSESSMENT; HEALTH HAZARD; HEALTH SURVEY; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; SMOKING; TOBACCO; XENOBIOTIC METABOLISM; BLOOD; CIGARETTE SMOKING; EXPOSURE; INFLAMMATION; PASSIVE SMOKING;

BIOMARKERS; CIGARETTE SMOKING; HEALTH SURVEYS; HUMANS; INFLAMMATION; INHALATION EXPOSURE; LEUKOCYTE COUNT; LIPOPROTEINS, HDL; TOBACCO SMOKE POLLUTION;

EID: 84978513216     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/1354750X.2016.1201536     Document Type: Article

References (59)

1. Abel GA, Hays JT, Decker PA, et al. (2005). Effects of biochemically confirmed smoking cessation on white blood cell count. Mayo Clin Proc 80:1022–8.
2. Albanes D, Jones DY, Micozzi MS, Mattson ME., (1987). Associations between smoking and body weight in the US population:analysis of NHANES II. Am J Public Health 77:439–44.
3. American Lung Association. (2015). Smoking facts. [Online] Available from:http://wwwlungorg/stop-smoking/smoking-facts/ [last accessed 22 Nov 2015].
4. Barter P., (2011). HDL-C:role as a risk modifier. Atheroscler Suppl 12:267–70.
5. Benowitz NL, Bernert JT, Caraballo RS, et al. (2009). Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol 169:236–48.
6. Benowitz NL, Jacob P., III. (1994). Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56:483–93.
7. Benowitz NL, Jacob P., III. (2001). Trans-3'-hydroxycotinine:disposition kinetics, effects and plasma levels during cigarette smoking. Br J Clin Pharmacol 51:53–9.
8. Bevilacqua MP, Pober JS, Wheeler ME, Jr., et al. (1985). Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 76:2003–11.
9. Brandt HC, Watson WP., (2003). Monitoring human occupational and environmental exposures to polycyclic aromatic compounds. Ann Occup Hyg 47:349–78.
10. Brown DW, Giles WH, Croft JB., (2001). White blood cell count:an independent predictor of coronary heart disease mortality among a national cohort. J Clin Epidemiol 54:316–22.
11. Calapai G, Caputi AP, Mannucci C, et al. (2009). Cardiovascular biomarkers in groups of established smokers after a decade of smoking. Basic Clin Pharmacol Toxicol 104:322–8.
12. Centers for Disease Control. (2015). National Health and Nutrition Examination Survey Data (NHANES). [Online] Available from:http://wwwcdcgov/nchs/nhaneshtm [last accessed 22 Nov 2015].
13. Centers for Disease Control and Prevention. (2010). How tobacco smoke causes disease:The biology and behavioral basis for smoking - attributable disease:A Report of the Surgeon General. [Online] Available from:http://www ncbi nlm nih gov/books/NBK53017/ [last accessed 22 Nov 2015].
14. Charland SL, Malone DC., (2010). Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Curr Med Res Opin 26:365–75.
15. Clair C, Bitton A, Meigs JB, Rigotti NA., (2011). Relationships of cotinine and self-reported cigarette smoking with hemoglobin A1c in the US:results from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 34:2250–5.
16. Eliasson B, Hjalmarson A, Kruse E, et al. (2001). Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res 3:249–55.
17. Forey BA, Fry JS, Lee PN, et al. (2013). The effect of quitting smoking on HDL-cholesterol:a review based on within-subject changes. Biomark Res 1:26.
18. Forte TM, Subbanagounder G, Berliner JA, et al. (2002). Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 43:477–85.
19. Frost-Pineda K, Liang Q, Liu J, et al. (2011). Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob Res 13:182–93.
20. Ginsberg G, Hattis D, Sonawane B., (2004). Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. Toxicol Appl Pharmacol 198:164–83.
21. Gordon T, Kannel WB., (1982). Multiple risk functions for predicting coronary heart disease:the concept, accuracy, and application. Am Heart J 103:1031–9.
22. Graeter LJ, Mortensen ME., (1996). Kids are different:developmental variability in toxicology. Toxicology 111:15–20.
23. Hatsukami DK, Benowitz NL, Rennard SI, et al. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res 8:600–22.
24. Hecht SS., (2002). Human urinary carcinogen metabolites:biomarkers for investigating tobacco and cancer. Carcinogenesis 23:907–22.
25. Hecht SS, Carmella SG, Chen M, et al. (1999). Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 59:590–6.
26. Hecht SS, Carmella SG, Murphy SE, et al. (1993). A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. N Engl J Med 329:1543–6.
27. Hessler JR, Robertson AL, Jr., Chisolm GM., III. (1979). LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32:213–29.
28. Hlatky MA, Greenland P, Arnett DK, et al. (2009). Criteria for evaluation of novel markers of cardiovascular risk:a scientific statement from the American Heart Association. Circulation 119:2408–16.
29. Ind PW., (2005). COPD disease progression and airway inflammation:uncoupled by smoking cessation. Eur Respir J 26:764–6.
30. Institute of Medicine. (2001). Clearing the smoke. In:Stratton K, Shetty P, Wallace R, Bondurant S, eds. Assessing the science base for tobacco harm reduction. Washington, DC:National Academy Press.
31. International Agency for Research on Cancer. (2010). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Ingested Nitrate and Nitrite, and Cyanobacterial Peptide Toxins. Volume 94. Lyon, France:International Agency for Research on Cancer.
32. Jain RB., (2015). Serum cotinine and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol levels among non-Hispanic Asian American smokers and nonsmokers as compared to other race/ethnicities:data from NHANES 2011-2012. Chemosphere 120:584–91.
33. Jedrychowski W, Whyatt RM, Cooper TB, et al. (1998). Exposure misclassification error in studies on prenatal effects of tobacco smoking in pregnancy and the birth weight of children. J Expo Anal Environ Epidemiol 8:347–57.
34. Johnson HM, Gossett LK, Piper ME, et al. (2010a). Effects of smoking and smoking cessation on endothelial function:1-year outcomes from a randomized clinical trial. J Am Coll Cardiol 55:1988–95.
35. Johnson HM, Piper ME, Jorenby DE, et al. (2010b). Risk factors for subclinical carotid atherosclerosis among current smokers. Prev Cardiol 13:166–71.
36. Jongeneelen FJ., (1994). Biological monitoring of environmental exposure to polycyclic aromatic hydrocarbons; 1-hydroxypyrene in urine of people. Toxicol Lett 72:205–11.
37. Khariwala SS, Scheuermann TS, Berg CJ, et al. (2014). Cotinine and tobacco-specific carcinogen exposure among nondaily smokers in a multiethnic sample. Nicotine Tob Res 16:600–5.
38. Lee G, Walser TC, Dubinett SM., (2009). Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 15:303–7.
39. Liu J, Liang Q, Frost-Pineda K, et al. (2011). Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol Biomarkers Prev 20:1760–9.
40. Lowe FJ, Gregg EO, McEwan M., (2009). Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med 47:311–120.
41. Madsen C, Nafstad P, Eikvar L, et al. (2007). Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study. Eur J Epidemiol 22:311–17.
42. Margolis KL, Manson JE, Greenland P, et al. (2005). Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women:the Women's Health Initiative Observational Study. Arch Intern Med 165:500–8.
43. Martinez-Sanchez JM, Ballbe M, Fu M, et al. (2014). Electronic cigarette use among adult population:a cross-sectional study in Barcelona, Spain (2013-2014). BMJ Open 4:e005894.
44. National Institutes of Health (1998). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults–the evidence report. Obes Res 6 Suppl:51S–209S.
45. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM., (2011). HDL and cardiovascular disease:atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8:222–32.
46. O'Connor RJ, Giovino GA, Kozlowski LT, et al. (2006). Changes in nicotine intake and cigarette use over time in two nationally representative cross-sectional samples of smokers. Am J Epidemiol 164:750–9.
47. Pelkonen O, Nebert DW., (1982). Metabolism of polycyclic aromatic hydrocarbons:etiologic role in carcinogenesis. Pharmacol Rev 34:189–222.
48. Rodgman A, Smith CJ, Perfetti TA., (2000). The composition of cigarette smoke:a retrospective, with emphasis on polycyclic components. Hum Exp Toxicol 19:573–95.
49. Roethig HJ, Feng S, Liang Q, et al. (2008). A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. J Clin Pharmacol 48:580–91.
50. Roethig HJ, Munjal S, Feng S, et al. (2009). Population estimates for biomarkers of exposure to cigarette smoke in adult US cigarette smokers. Nicotine Tob Res 11:1216–25.
51. Sarkar M, Kapur S, Frost-Pineda K, et al. (2008). Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob Res 10:1761–72.
52. Sarkar M, Liu J, Koval T, et al. (2010). Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. Nicotine Tob Res 12:105–16.
53. St. Helen G, Goniewicz ML, Dempsey D, et al. (2012). Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. Chem Res Toxicol 25:952–64.
54. Strickland P, Kang D., (1999). Urinary 1-hydroxypyrene and other PAH metabolites as biomarkers of exposure to environmental PAH in air particulate matter. Toxicol Lett 108:191–9.
55. Tall AR, Yvan-Charvet L, Terasaka N, et al. (2008). HDL, ABC transporters, and cholesterol efflux:implications for the treatment of atherosclerosis. Cell Metab 7:365–75.
56. Tamakoshi K, Toyoshima H, Yatsuya H, et al. (2007). White blood cell count and risk of all-cause and cardiovascular mortality in nationwide sample of Japanese-results from the NIPPON DATA90. Circ J 71:479–85.
57. World Health Organization. (2007). The Scientific Basis of Tobacco Product Regulation:Report of a WHO Study Group. WHO Technical Report Series. Vol. 945. Geneva:World Health Organization.
58. Yasue H, Hirai N, Mizuno Y, et al. (2006). Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers. Circ J 70:8–13.
59. Yuan JM, Butler LM, Gao YT, et al. (2014). Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung cancer development in lifelong never smokers in the Shanghai cohort study. Carcinogenesis 35:339–45.